Latest net income for CINC: $-93M, below the sector sector average of $90M.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2022
Trailing 12 months ending Sep 2022
Loading...
Loading...
As of the most recent data (September 2022), CINC shows a net income of $-93M. That compares with $-27M in the prior-year period — down 247.7% year over year. That is below the sector sector average of $90M. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CINC's net income is now $-93M (was $-27M) — a 247.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether CinCor Pharma is outperforming or lagging.
The its sector sector average net income is about $90M. CinCor Pharma is at $-93M, which is lower that average. That is roughly 203.4% below the sector mean. Use the comparison chart on this page to see how CINC stacks up against individual peers as well.
Tracking CINC's net income over time shows whether CinCor Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-93M That compares with $-27M in the prior-year period — down 247.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net income page, Stockcircle has CinCor Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-93M) with ownership activity and broader fundamentals.